AbbVie Inc. (ABBV)

93.01
1.31 1.39
NYSE : Health Technology
Prev Close 94.32
Open 94.38
Day Low/High 91.40 / 94.53
52 Wk Low/High 63.29 / 125.86
Volume 4.96M
Avg Volume 7.52M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 146.93B
EPS 3.30
P/E Ratio 28.36
Div & Yield 3.84 (2.84%)

Latest News

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

AbbVie Announces Global Resolution Of HUMIRA® (adalimumab) Patent Disputes With Samsung Bioepis

AbbVie Announces Global Resolution Of HUMIRA® (adalimumab) Patent Disputes With Samsung Bioepis

- Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates

Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction

Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction

These names are displaying signs of either bullish or bearish reversal patterns over the past week.

Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom

Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom

The legal cannabis industry could be worth $24 billion by 2025. Are you willing to pass that up?

4 Strong Buy Biotech Stocks Poised to Explode

4 Strong Buy Biotech Stocks Poised to Explode

Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

Here's what you need to know now for Thursday, March 22.

Jim Cramer: When There's Nothing to Buy, People Sell

Jim Cramer: When There's Nothing to Buy, People Sell

No sector offered respite from Thursday's tariff-inspired selloff.

AbbVie's Cancer Drug Setback Provides Buying Opportunity

AbbVie's Cancer Drug Setback Provides Buying Opportunity

The biopharma company's shares took a dive on Thursday, March 22, after it said it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small-cell lung cancer.

Jim Cramer: No Place to Go and Fewer Places to Hide

Jim Cramer: No Place to Go and Fewer Places to Hide

Just not a great day.

AbbVie And The International Myeloma Foundation Announce Partnership To Study The Role Of A Genetic Mutation In Outcomes Of Patients With Multiple Myeloma

AbbVie And The International Myeloma Foundation Announce Partnership To Study The Role Of A Genetic Mutation In Outcomes Of Patients With Multiple Myeloma

- Study is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally

AbbVie Announces Positive Topline Results From Second Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

AbbVie Announces Positive Topline Results From Second Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

- Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

Julianne Hough Encourages Women To "Speak Up For Endo" During Endometriosis Awareness Month

Julianne Hough Encourages Women To "Speak Up For Endo" During Endometriosis Awareness Month

- Endometriosis affects an estimated one in 10 women of reproductive age, but diagnosis can take up to six to 10 years(1,2)

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal Of Marketing Authorizations For ZINBRYTA® (daclizumab) For Relapsing Multiple Sclerosis

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal Of Marketing Authorizations For ZINBRYTA® (daclizumab) For Relapsing Multiple Sclerosis

Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis.

AbbVie And Voyager Therapeutics Announce Global Strategic Collaboration To Develop Potential New Treatments For Alzheimer's Disease And Other Tau-Related Neurodegenerative Diseases

AbbVie And Voyager Therapeutics Announce Global Strategic Collaboration To Develop Potential New Treatments For Alzheimer's Disease And Other Tau-Related Neurodegenerative Diseases

Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

AbbVie Appears Ready to Start a New Advance at Any Time

AbbVie Appears Ready to Start a New Advance at Any Time

Traders should still be long and looking for higher highs. Let's check the charts and indicators again.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

TheStreet Quant Rating: B (Buy)